US5916588A
(en)
*
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
US6090406A
(en)
*
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
CA1267087A
(en)
*
|
1985-02-14 |
1990-03-27 |
Nicolaas Visser |
Synthetic immunogen
|
DE3601136A1
(de)
*
|
1986-01-16 |
1987-07-23 |
Max Planck Gesellschaft |
Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
|
US4803070A
(en)
*
|
1986-04-15 |
1989-02-07 |
Ribi Immunochem Research Inc. |
Immunological emulsion adjuvants for polysaccharide vaccines
|
US5554372A
(en)
*
|
1986-09-22 |
1996-09-10 |
Emory University |
Methods and vaccines comprising surface-active copolymers
|
US6054438A
(en)
*
|
1987-01-07 |
2000-04-25 |
Imperial Cancer Research Technology Limited |
Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
|
US5434182A
(en)
*
|
1987-12-31 |
1995-07-18 |
Isaacs; Charles E. |
Antibacterial fatty acid compositions
|
US4997851A
(en)
*
|
1987-12-31 |
1991-03-05 |
Isaacs Charles E |
Antiviral and antibacterial activity of fatty acids and monoglycerides
|
US5466714A
(en)
*
|
1987-12-31 |
1995-11-14 |
Research Foundation For Mental Health Hygiene, Inc. |
Spermicidal and cytocidal fatty acid compositions
|
EP0324455A3
(en)
*
|
1988-01-15 |
1991-03-27 |
Hans O. Ribi |
Novel polymeric immunological adjuvants
|
JPH04501663A
(ja)
*
|
1988-09-23 |
1992-03-26 |
ユニバーシティ・オブ・サザン・カリフォルニア |
黒色腫用免疫療法ワクチン
|
FI902821A7
(fi)
*
|
1989-06-12 |
1990-12-13 |
Res Foundation For Mental Hygiene |
Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
|
DE4007315A1
(de)
*
|
1990-03-08 |
1991-09-12 |
Behringwerke Ag |
Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
|
US5091188A
(en)
*
|
1990-04-26 |
1992-02-25 |
Haynes Duncan H |
Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
|
US5246707A
(en)
*
|
1990-04-26 |
1993-09-21 |
Haynes Duncan H |
Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
|
SK100893A3
(en)
|
1991-03-19 |
1994-04-06 |
Cytrx Corp |
Polyoxypropylene-polyoxyethylene copolymers with improved biological activity
|
CA2108266C
(en)
*
|
1991-04-19 |
2003-06-03 |
Albert J. Owen |
Convertible microemulsion formulations
|
US5688761A
(en)
*
|
1991-04-19 |
1997-11-18 |
Lds Technologies, Inc. |
Convertible microemulsion formulations
|
IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
FR2702373B1
(fr)
*
|
1993-03-08 |
1996-06-07 |
Rhone Merieux |
Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
|
KR100310510B1
(ko)
*
|
1993-03-23 |
2002-07-04 |
장 스테판느 |
3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
|
WO1994027635A1
(en)
*
|
1993-05-27 |
1994-12-08 |
Entremed, Inc. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
US5718904A
(en)
*
|
1995-06-02 |
1998-02-17 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
US5690942A
(en)
*
|
1995-06-02 |
1997-11-25 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
AU709262B2
(en)
*
|
1995-10-17 |
1999-08-26 |
Board Of Regents, The University Of Texas System |
Insoluble drug delivery
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US5849307A
(en)
*
|
1997-03-26 |
1998-12-15 |
The Picower Institute For Medical Research |
Vaccine adjuvant
|
US6455323B1
(en)
|
1997-07-03 |
2002-09-24 |
Pharmacia & Upjohn Company |
Anti-bacterial methods and materials
|
EP1054678B1
(en)
*
|
1998-02-11 |
2003-05-28 |
RTP Pharma Corporation |
Combination of steroid and polyunsaturated fatty acids for treatment of inflammatory conditions
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
JP2002516267A
(ja)
|
1998-05-29 |
2002-06-04 |
アールティーピー・ファーマ・インコーポレーテッド |
熱的に保護された微粒子組成物及びその最終蒸気滅菌
|
AU759641B2
(en)
|
1998-08-19 |
2003-04-17 |
Skyepharma Canada Inc. |
Injectable aqueous dispersions of propofol
|
GB2348203B
(en)
|
1998-11-04 |
2002-06-19 |
Imp College Innovations Ltd |
Solube beta-forms of prion proteins, methods of preparation and use
|
NZ511792A
(en)
|
1998-11-20 |
2003-08-29 |
Skyepharma Canada Inc |
Dispersible phospholipid stabilized microparticles
|
US6790950B2
(en)
|
1999-04-09 |
2004-09-14 |
Pharmacia & Upjohn Company |
Anti-bacterial vaccine compositions
|
EP1860117A3
(en)
|
1999-04-09 |
2008-09-03 |
Pharmacia & Upjohn Company LLC |
Anti-bacterial vaccine compositions
|
EP1214059B1
(en)
*
|
1999-09-21 |
2005-05-25 |
Skyepharma Canada Inc. |
Surface modified particulate compositions of biologically active substances
|
AU2001256957B2
(en)
|
2000-03-17 |
2005-08-25 |
Pharmacia & Upjohn Company Llc |
Salmonella vaccine materials and methods
|
US6764823B2
(en)
|
2000-04-06 |
2004-07-20 |
Pharmacia & Upjohn Company |
Antimicrobial methods and materials
|
AU2001257115B2
(en)
|
2000-04-20 |
2005-01-27 |
Rtp Pharma Inc. |
Improved water-insoluble drug particle process
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
EP1313451B1
(en)
|
2000-08-31 |
2009-03-11 |
Jagotec AG |
Milled particles
|
US8586094B2
(en)
*
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
ATE522211T1
(de)
*
|
2000-09-20 |
2011-09-15 |
Jagotec Ag |
Stabilisierte fibrat-mikropartikel
|
ATE357216T1
(de)
*
|
2001-02-22 |
2007-04-15 |
Jagotec Ag |
Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
|
FR2824279B1
(fr)
*
|
2001-05-04 |
2004-05-28 |
Seppic Sa |
Emulsion e/h concentree
|
GB0112126D0
(en)
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
FR2824269B1
(fr)
*
|
2001-09-03 |
2012-03-02 |
Seppic Sa |
Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
|
WO2004064759A2
(en)
|
2003-01-21 |
2004-08-05 |
Chiron Corporation |
Use of tryptanthrin compounds for immune potentiation
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
GB0315323D0
(en)
|
2003-07-01 |
2003-08-06 |
Royal Veterinary College |
Vaccine composition
|
US9023366B2
(en)
|
2003-07-01 |
2015-05-05 |
The Royal Veterinary College |
Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
US20060210590A1
(en)
|
2005-02-03 |
2006-09-21 |
Alk-Abello A/S |
Minor allergen control to increase safety of immunotherapy
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
EP2010530A2
(en)
*
|
2006-03-23 |
2009-01-07 |
Novartis AG |
Methods for the preparation of imidazole-containing compounds
|
ES2588705T3
(es)
*
|
2007-09-27 |
2016-11-04 |
Immunovaccine Technologies Inc. |
Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
US20110070298A1
(en)
|
2008-06-05 |
2011-03-24 |
Immunovaccine Technologies Inc. |
Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
|
EP2818469B1
(en)
|
2008-12-09 |
2017-02-15 |
Gilead Sciences, Inc. |
Intermediates for the preparation of modulators of toll-like receptors
|
CN102300483B
(zh)
|
2010-01-29 |
2015-08-19 |
株式会社御木本 |
装饰品用卡扣
|
JP6030052B2
(ja)
|
2010-05-14 |
2016-11-24 |
バクスアルタ インコーポレイテッド |
Ospaキメラおよびそのワクチンでの使用法
|
WO2012010291A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
WO2012010290A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
EP2462950A1
(en)
|
2010-12-08 |
2012-06-13 |
Neovacs |
Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
|
US20130259892A1
(en)
|
2010-12-08 |
2013-10-03 |
Geraldine Grouard-Vogel |
Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
|
DK2694094T3
(da)
|
2011-04-07 |
2017-11-13 |
Neovacs |
FREMGANGSMÅDE TIL BEHANDLING AF IFN-alpha-RELATEREDE TILSTANDE
|
EP2508197A1
(en)
|
2011-04-07 |
2012-10-10 |
Neovacs |
Method for treating IFNalpha related conditions
|
WO2013049941A1
(en)
|
2011-10-06 |
2013-04-11 |
Immunovaccine Technologies Inc. |
Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
|
GB201200259D0
(en)
|
2012-01-09 |
2012-02-22 |
Ohlin Per M |
Novel therapies
|
KR20150038380A
(ko)
|
2012-07-27 |
2015-04-08 |
백스터 인터내셔널 인코포레이티드 |
키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
WO2016059161A1
(en)
|
2014-10-15 |
2016-04-21 |
Xenothera |
Composition with reduced immunogenicity
|
AR114911A1
(es)
|
2018-06-04 |
2020-10-28 |
Apros Therapeutics Inc |
Conjugados peptídicos de tlr7
|
JP7728560B2
(ja)
|
2018-07-02 |
2025-08-25 |
アユヴィス リサーチ インク. |
新規免疫調節小分子
|
EP3922255A1
(en)
|
2020-06-10 |
2021-12-15 |
Prokarium Limited |
Cancer therapy
|
GB202009411D0
(en)
|
2020-06-19 |
2020-08-05 |
Prokarium Ltd |
Autotransporter systems
|
CN112807426A
(zh)
*
|
2021-01-26 |
2021-05-18 |
郭志文 |
一种基于动物疫苗的聚合物佐剂、制备方法及其应用
|
EP4124342A1
(en)
|
2021-07-28 |
2023-02-01 |
Prokarium Limited |
Cancer therapy with live attenuated bacteria
|
WO2023036814A1
(en)
|
2021-09-07 |
2023-03-16 |
Universite De Tours |
Coronavirus fusion protein
|
GB202215134D0
(en)
|
2022-10-13 |
2022-11-30 |
Prokarium Ltd |
Composition
|
GB202215576D0
(en)
|
2022-10-21 |
2022-12-07 |
Prokarium Ltd |
Circuit
|
WO2025068413A1
(en)
|
2023-09-28 |
2025-04-03 |
Prokarium Limited |
Interleukin 18 variants
|
WO2025068401A1
(en)
|
2023-09-28 |
2025-04-03 |
Prokarium Limited |
Interleukin 15 variant
|
WO2025109155A1
(en)
|
2023-11-24 |
2025-05-30 |
Prokarium Limited |
Interleukin variant
|